Symbols / MNPR Stock $54.02 +1.54% Monopar Therapeutics Inc.

Healthcare • Biotechnology • United States • NCM
MNPR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Chandler D. Robinson M.B.A., M.D., M.…
Exch · Country NCM · United States
Market Cap 361.51M
Enterprise Value 221.36M
Income -13.72M
Sales —
FCF (ttm) -8.20M
Book/sh 20.59
Cash/sh 20.98
Employees 22
Insider 10d —
IPO Dec 19, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -14.88
PEG —
P/S —
P/B 2.62
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 51.33
Current Ratio 51.35
Debt/Eq 0.18
LT Debt/Eq —
EPS (ttm) -1.85
EPS next Y -3.63
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2026-03-27
ROA -10.39%
ROE -14.22%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 6.69M
Shs Float 4.40M
Insider Own 23.69%
Instit Own 83.08%
Short Float 68.61%
Short Ratio 8.63
Short Interest 1.72M
52W High 105.00
vs 52W High -48.55%
52W Low 28.40
vs 52W Low 90.21%
Beta 1.66
Impl. Vol. —
Rel Volume 0.29
Avg Volume 207.26K
Volume 60.39K
Target (mean) $112.79
Tgt Median $112.00
Tgt Low $100.00
Tgt High $130.00
# Analysts 14
Recom Strong_buy
Prev Close $53.20
Price $54.02
Change 1.54%
About

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$112.79
Mean price target
2. Current target
$54.02
Latest analyst target
3. DCF / Fair value
$-22.05
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$54.02
Low
$100.00
High
$130.00
Mean
$112.79

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-30 main Chardan Capital Buy → Buy $100
2026-02-23 reit BTIG Buy → Buy $104
2026-02-02 reit BTIG Buy → Buy $104
2026-01-29 main Chardan Capital Buy → Buy $100
2026-01-14 reit BTIG Buy → Buy $104
2026-01-09 init Morgan Stanley — → Overweight $115
2025-11-14 down Raymond James Strong Buy → Outperform $123
2025-11-13 main Chardan Capital Buy → Buy $100
2025-11-10 init Leerink Partners — → Outperform $115
2025-11-09 main Chardan Capital Buy → Buy $100
2025-10-13 init Barclays — → Overweight $125
2025-10-06 main Raymond James Strong Buy → Strong Buy $142
2025-10-02 main Oppenheimer Outperform → Outperform $115
2025-09-29 main HC Wainwright & Co. Buy → Buy $105
2025-09-25 main Piper Sandler Overweight → Overweight $95
2025-09-25 main BTIG Buy → Buy $104
2025-09-25 main Chardan Capital Buy → Buy $85
2025-09-23 init Lake Street — → Buy $106
2025-09-16 main Chardan Capital Buy → Buy $60
2025-09-15 reit BTIG Buy → Buy $87
News
RSS: Latest MNPR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-31 ROBINSON CHANDLER D Chief Executive Officer — 6,732 — —
2026-03-31 CITTADINE ANDREW Chief Operating Officer — 3,514 — —
2025-12-31 ROBINSON CHANDLER D Chief Executive Officer — 8,724 — —
2025-12-31 CITTADINE ANDREW Chief Operating Officer — 4,326 — —
2025-12-26 VU QUAN ANH Chief Financial Officer — 1,500 $69.95 $104,925
2025-12-18 KLAUSNER ARTHUR J Director — 5,121 $67.06 $343,889
2025-09-30 ROBINSON CHANDLER D Chief Executive Officer — 8,726 — —
2025-09-30 CITTADINE ANDREW Chief Operating Officer — 4,327 — —
2025-09-24 TACTIC PHARMA, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 550,229 $63.61 $34,999,957
2025-07-14 STARR CHRISTOPHER M Director — 16,800 $40.00 $672,020
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
16.70
+3.36%
16.16
+83.01%
8.83
-16.19%
10.54
Research And Development
9.90
-23.85%
13.01
+132.24%
5.60
-26.23%
7.59
Selling General And Administration
6.80
+115.49%
3.16
-2.33%
3.23
+9.70%
2.95
General And Administrative Expense
6.80
+115.49%
3.16
-2.33%
3.23
+9.70%
2.95
Other Gand A
6.80
+115.49%
3.16
-2.33%
3.23
+9.70%
2.95
Total Expenses
16.70
+3.36%
16.16
+83.01%
8.83
-16.19%
10.54
Operating Income
-16.70
-3.36%
-16.16
-83.01%
-8.83
+16.19%
-10.54
Total Operating Income As Reported
-16.70
-3.36%
-16.16
-83.01%
-8.83
+16.19%
-10.54
EBITDA
-16.70
-3.36%
-16.16
-83.01%
-8.83
+16.19%
-10.54
Normalized EBITDA
-16.70
-3.36%
-16.16
-83.01%
-8.83
+16.19%
-10.54
EBIT
-16.70
-3.36%
-16.16
-83.01%
-8.83
+16.19%
-10.54
Total Unusual Items
—
—
—
—
Total Unusual Items Excluding Goodwill
—
—
—
—
Special Income Charges
—
—
—
—
Net Income
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Pretax Income
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Net Non Operating Interest Income Expense
2.99
+639.45%
0.40
-5.83%
0.43
+1920.05%
0.02
Net Interest Income
2.99
+639.45%
0.40
-5.83%
0.43
+1920.05%
0.02
Interest Income Non Operating
2.99
+639.45%
0.40
-5.83%
0.43
+1920.05%
0.02
Interest Income
2.99
+639.45%
0.40
-5.83%
0.43
+1920.05%
0.02
Other Income Expense
—
0.17
—
—
Other Non Operating Income Expenses
—
0.17
—
—
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Net Income From Continuing Operation Net Minority Interest
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Net Income From Continuing And Discontinued Operation
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Net Income Continuous Operations
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Normalized Income
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Net Income Common Stockholders
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Diluted EPS
-1.85
+54.99%
-4.11
-35.20%
-3.04
+26.75%
-4.15
Basic EPS
-1.85
+54.99%
-4.11
-35.20%
-3.04
+26.75%
-4.15
Basic Average Shares
7.41
+95.53%
3.79
+37.09%
2.76
+8.69%
2.54
Diluted Average Shares
7.41
+95.53%
3.79
+37.09%
2.76
+8.69%
2.54
Diluted NI Availto Com Stockholders
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
140.72
+133.40%
60.29
+720.83%
7.35
-44.47%
13.23
Current Assets
140.46
+132.97%
60.29
+722.24%
7.33
-44.31%
13.17
Cash Cash Equivalents And Short Term Investments
140.40
+133.17%
60.21
+728.68%
7.27
-44.62%
13.12
Cash And Cash Equivalents
61.83
+34.96%
45.82
+530.55%
7.27
-11.24%
8.19
Other Short Term Investments
78.57
+445.75%
14.40
0.00
-100.00%
4.93
Other Current Assets
0.06
-19.18%
0.08
+18.72%
0.07
+44.48%
0.05
Total Non Current Assets
0.25
0.00
-100.00%
0.01
-79.35%
0.06
Net PPE
0.25
0.00
-100.00%
0.01
-79.35%
0.06
Gross PPE
0.25
0.00
-100.00%
0.01
-79.35%
0.06
Properties
—
—
0.00
0.00
Buildings And Improvements
—
—
0.01
-79.35%
0.06
Other Properties
0.25
—
0.01
-79.35%
0.06
Total Liabilities Net Minority Interest
2.89
-44.99%
5.25
+198.98%
1.76
-43.98%
3.14
Current Liabilities
2.74
-47.94%
5.25
+198.98%
1.76
-43.83%
3.13
Payables And Accrued Expenses
2.74
-47.94%
5.25
+198.98%
1.76
-43.83%
3.13
Payables
2.74
+21.33%
2.25
+28.28%
1.76
-43.83%
3.13
Accounts Payable
2.74
+21.33%
2.25
+28.28%
1.76
-43.83%
3.13
Current Accrued Expenses
0.00
-100.00%
3.00
0.00
—
Total Non Current Liabilities Net Minority Interest
0.15
0.00
0.00
-100.00%
0.01
Long Term Debt And Capital Lease Obligation
0.15
0.00
0.00
-100.00%
0.01
Long Term Capital Lease Obligation
0.15
0.00
0.00
-100.00%
0.01
Stockholders Equity
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Common Stock Equity
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Capital Stock
0.01
+9.65%
0.01
+104.73%
0.00
-76.98%
0.01
Common Stock
0.01
+9.65%
0.01
+104.73%
0.00
-76.98%
0.01
Share Issued
6.69
+9.66%
6.10
+104.72%
2.98
+15.12%
2.59
Ordinary Shares Number
6.69
+9.66%
6.10
+104.72%
2.98
+15.12%
2.59
Additional Paid In Capital
227.20
+73.72%
130.79
+98.75%
65.81
+6.36%
61.87
Retained Earnings
-89.51
-18.10%
-75.79
-25.89%
-60.21
-16.22%
-51.80
Gains Losses Not Affecting Retained Earnings
0.13
+265.05%
0.04
+354.68%
-0.01
-258.04%
0.01
Other Equity Adjustments
0.13
+265.05%
0.04
+354.68%
-0.01
-258.04%
0.01
Total Equity Gross Minority Interest
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Total Capitalization
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Working Capital
137.73
+150.25%
55.04
+887.19%
5.58
-44.45%
10.04
Invested Capital
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Total Debt
0.15
0.00
0.00
-100.00%
0.01
Capital Lease Obligations
0.15
0.00
0.00
-100.00%
0.01
Net Tangible Assets
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Tangible Book Value
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-12.20
-90.52%
-6.40
+18.50%
-7.86
-8.71%
-7.23
Cash Flow From Continuing Operating Activities
-12.20
-90.52%
-6.40
+18.50%
-7.86
-8.71%
-7.23
Net Income From Continuing Operations
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Other Non Cash Items
—
4.55
—
—
Stock Based Compensation
4.84
+324.08%
1.14
-39.89%
1.90
+15.63%
1.64
Change In Working Capital
-2.61
-174.49%
3.50
+358.37%
-1.35
-182.27%
1.65
Change In Payables And Accrued Expense
-2.61
-174.48%
3.51
+362.97%
-1.33
-190.21%
1.48
Change In Accrued Expense
-3.00
-200.00%
3.00
0.00
—
Change In Payable
0.39
-23.40%
0.51
+138.00%
-1.33
-190.21%
1.48
Change In Account Payable
0.39
-23.40%
0.51
+138.00%
-1.33
-190.21%
1.48
Change In Other Working Capital
-0.01
-322.56%
0.00
—
-0.00
Change In Other Current Assets
0.02
+220.57%
-0.01
+37.40%
-0.02
-111.88%
0.17
Investing Cash Flow
-63.45
-342.54%
-14.34
-390.97%
4.93
+200.19%
-4.92
Cash Flow From Continuing Investing Activities
-63.45
-342.54%
-14.34
-390.97%
4.93
+200.19%
-4.92
Net Investment Purchase And Sale
-63.45
-342.54%
-14.34
-390.97%
4.93
+200.19%
-4.92
Purchase Of Investment
-87.15
-468.73%
-15.32
-94.42%
-7.88
-60.25%
-4.92
Sale Of Investment
23.70
+2304.31%
0.99
-92.30%
12.81
0.00
Financing Cash Flow
91.57
+54.45%
59.29
+2824.80%
2.03
+6066.85%
0.03
Cash Flow From Continuing Financing Activities
91.57
+54.45%
59.29
+2824.80%
2.03
+6066.85%
0.03
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Long Term Debt Issuance
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
92.14
+55.13%
59.40
+2763.59%
2.07
+1797.07%
0.11
Common Stock Payments
-35.00
0.00
—
—
Repurchase Of Capital Stock
-35.00
0.00
—
—
Proceeds From Stock Option Exercised
0.57
+672722.62%
0.00
0.00
-100.00%
0.00
Net Other Financing Charges
-1.13
-986.49%
-0.10
-121.89%
-0.05
+38.71%
-0.08
Changes In Cash
15.92
-58.70%
38.55
+4367.57%
-0.90
+92.54%
-12.11
Effect Of Exchange Rate Changes
0.10
+19589.47%
0.00
+102.94%
-0.02
-382.92%
-0.00
Beginning Cash Position
45.82
+530.55%
7.27
-11.24%
8.19
-59.68%
20.30
End Cash Position
61.83
+34.96%
45.82
+530.55%
7.27
-11.24%
8.19
Free Cash Flow
-12.20
-90.52%
-6.40
+18.50%
-7.86
-8.71%
-7.23
Amortization Of Securities
-0.72
-7846.58%
-0.01
—
—
Common Stock Issuance
127.14
+114.06%
59.40
+2763.59%
2.07
+1797.07%
0.11
Issuance Of Capital Stock
127.14
+114.06%
59.40
+2763.59%
2.07
+1797.07%
0.11
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category